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Aspartame induces angiogenesis
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Abstract
Angiogenesis is the process of generating new blood vessels from preexisting vessels and is considered essen-
tial in many pathological conditions. The purpose of the present study is to evaluate the effect of aspartame on
angiogenesis in vivo chick chorioallantoic membrane (CAM) and wound-healing models as well as in vitro 2,3-
bis-2H-tetrazolium-5-carboxanilide (XTT) and tube formation assays. In CAM assay, aspartame increased
angiogenesis in a concentration-dependent manner. Compared with the control group, aspartame has signif-
icantly increased vessel proliferation (p < 0.001). In addition, in vivo rat model of skin wound-healing study
showed that aspartame group had better healing than control group, and this was statistically significant at
p < 0.05. There was a slight proliferative effect of aspartame on human umbilical vein endothelial cells on XTT
assay in vitro, but it was not statistically significant; and there was no antiangiogenic effect of aspartame on tube
formation assay in vitro. These results provide evidence that aspartame induces angiogenesis in vitro and in
vivo; so regular use may have undesirable effect on susceptible cases.
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Introduction
Aspartame is a food additive marketed under a few
brand names, and it has subsequently been approved
for use in a number of food products including multi-
vitamins, fruit juices, stick-type confections, breath
mints, and iced tea.1 Aspartame is a methyl ester of
an aspartic acid and phenylalanine dipeptide, used
as a synthetic nonnutritive sweetener in over 6000
products across 90 countries worldwide.2 Although
aspartame is used in many products for nearly
30 years, it is not clearly established whether it has
an undesirable effect. Recent study suggests that
useable aspartame extracts have angiogenic activity
in vitro.3 Angiogenesis is thought to be important
in some pathological processes such as chronic
inflammatory diseases, psoriasis, diabetic retinopa-
thy, and some cancers.4,5 If aspartame has a possible
inducing effect on angiogenesis, it may have unfa-
vorable long-term results on these patients. There-
fore, we aimed to examine the effects of aspartame
on angiogenesis in vivo chorioallantoic membrane
(CAM) model and rat model of skin wound healing;
in addition, in vitro 2,3-bis-2H-tetrazolium-5-
carboxanilide (XTT) assay and endothelial cell tube
formation assay were also studied.
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Aspartame was purchased from Bilim Pharmaceuti-
cals Corp. (Istanbul, Turkey). For XTT assay, various
aspartame solutions were prepared with serial dilu-
tions from a stock solution of 1 mM, which was pre-
pared by dissolving 6 mg aspartame in a final volume
of 20 mL solution. For other models, a stock solution
of 100 mM aspartame was prepared and various con-
centrations were used with dilutions.
Cell viability assay
Cell viability was evaluated using the XTT method.
Human umbilical vein endothelial cell (HUVEC;
100 mL) suspensions were plated in 96-well flat-
bottom tissue culture plates at a density of 4  104
cells/well. The cells were allowed to attach to the well
overnight and then treated with 100 mL of aspartame
solution at various concentrations (20, 40, 60, 80, and
100 mM) for 24–48 h. Then, 50mL of XTT reagent solu-
tion (Biological Industries, Israel) was added to each
well, and then the plate was incubated in a humidified
carbon dioxide incubator at 37C for 2–4 h. Control
wells were the wells containing the cells and the blank
background. Absorbance was read at 450 nm in an
enzyme-linked immunosorbent assay plate reader
(model ELx 800 bioelisa microplate reader; Biokit,
Spain), and the results were expressed as percentage
variation with respect to controls. The cell viability
was repeated in triplicate with three independent
experiments.
In vitro endothelial cell tube formation assay
BD Matrigel (BD cat. no.: 354234, USA; 50 mL)
matrix was plated in 96-well flat-bottom cell culture
cluster plates. After incubating for 30 min, 50 mL
HUVEC (10,000 cells/well) and 20 mL of 20 mM
aspartame solution were placed on matrigel. Control
group was prepared by following the same procedure
as mentioned previously except aspartame solution.
The plate was incubated at 37C for 16–18 h.6 Fol-
lowing incubation, the plated wells were photo-
graphed, and the results were evaluated.
CAM assay
Angiogenesis was evaluated in vivo using the CAM
assay. Atak-S fertilized chicken eggs were obtained
from Poultry Institution (Ankara, Turkey) and incubated
at 37C, and 85–90% of relative humidity were main-
tained throughout the experiment.
Aspartame with 6, 15, 30, and 60 mM concentra-
tions were prepared, and 50 mL of each solution was
used on CAMs.
Experiments were performed to determine the
mode of action of aspartame on vascular development
in the sixth day and seventh day on CAM. On the sixth
day, between 10 a.m. and 12 p.m., a window was
opened on each egg to allow subsequent access to the
CAM and 50 mL of test solution was placed on the sur-
face of each CAM.7 Some control CAMs received
phosphate-buffered saline (PBS), and then all the eggs
were sealed with a transparent tape. On day 7, CAMs
were screened and taken pictures using a computer-
aided stereomicroscope (model S6D; Leica Microsys-
tems, Heerbrugg, Switzerland). The captured images
were processed with the software Leica Application
Suite V4 Automated Image Analysis (Leica Micro-
systems). Finally, the increase in vessel formation
was scored.8
Rat model of skin wound healing
Male Sprague Dawley rats, aged 8 weeks and weigh-
ing 200–250 g, were used for this model. They were
anesthetized by intraperitoneal injection of ketamine
(90 mg/kg) and xylazine (10 mg/kg). Before excision,
the surgical area, which is the skin over the dorsal area,
was shaved off and disinfected with 70% ethanol. With
the help of a biopsy punch and dissecting scissors, two
round sections of 5 mm diameter full thickness skin
were excised from each rat.9 Each rat had two groups
of wounds: control wound (treated with PBS) and
aspartame-treated wound. Aspartame-treated wounds
received 50 mL of 50 mM aspartame solution. The
same treatment protocol was applied for 7 days. On day
8, the surface area of each wound was calculated and
the wounds were harvested. All specimens were fixed
in 10% formalin. After getting thin perpendicular sec-
tions, embedding in paraffin and deparaffinization pro-
cedures were carried out, and the specimens were
stained with hematoxylin and eosin in Department of
Pathology of Gülhane Military Medical Academy. His-
topathological examination for all slides was
carried out under a light microscope by a pathologist
blinded to the groups. The wound-healing process was
scored according to the following parameters: re-
epithelization, granulation tissue formation, collagen
deposition, inflammatory cells, and angiogenesis.10,11
Also, the wound areas were statistically compared. The
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procedures in this study were approved by the Local
Animal Ethics Committee.
Statistics
The statistical analysis was carried out using Statisti-
cal Package for the Social Sciences software for Win-
dows, Version 15.00 (SPSS Inc., Chicago, Illinois,
USA). The value of p  0.05 was considered statisti-
cally significant.
Results
Cell viability assay of aspartame
HUVECs were incubated with increasing doses of
aspartame for 24–48 h, and cell viability was
observed with the XTT assay. There is a slight prolif-
erative effect on HUVECs in the presence of aspar-
tame for 24 h, but it was not statistically significant
(Figure 1).
Effect of aspartame on tube formation
In the tube formation assay, on the 18th hour of incu-
bation, the results were evaluated. Comparing the
tube length/area ratio values of control and aspartame
groups, there was no significant statistical difference.
So, it was found that aspartame had no antiangiogenic
effect (Figures 2 and 3).
Aspartame induces angiogenesis on CAM
To determine the mode of action and dose depen-
dency of drug during days 6 and 7 on CAMs, we
applied various concentrations of aspartame solu-
tion to CAMs on day 6 and evaluated their effects
on CAM vessels growth, angiogenesis on day 7. On
day 7, the treatment of CAMs with aspartame solu-


























Figure 1. Cell proliferation of HUVECs under aspartame
incubation (cell viability was indicated as percentage of






















Figure 2. Ratio of tube length to area under aspartame
incubation and control.
Figure 3. Tube formations of control group (a) and under
aspartame incubation (b).
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in CAM vascular area. The increase in vessel forma-
tion was scored.8 While physiological angiogenesis
was observed in the form of some allantoic vessels
in the control group (score 0), a significant increase
in CAM area of eggs treated with aspartame solu-
tion was appreciable macroscopically (score þ2).
Significant growth was seen for 60 mM aspartame
solution.
In affected CAMs, the vessels were thicker and
showed more branching (Figure 4). Efficacy was not
enough for low doses; while there was a significant
increase for high doses in comparison with the control
group. Aspartame caused a significant increase in
blood vessels when compared with the control group.
However, the lower doses of drug did not show dis-
cernible effect on blood vessel pattern.
The efficacies at different doses were compared
using 2 test, and there was a statistically significant
difference (Yates correction 2 ¼ 10.60, p ¼ 0.001).
The efficacy of increasing dose was evaluated with
Spearman’s correlation test and a strong relation was
found (r ¼ 0.704, p ¼ 0.001). Macroscopically evalu-
ated results of CAMs are shown in Table 1.
Aspartame may have a healing effect on wounds
by angiogenesis
Aspartame-treated wounds were found to heal better
than the control group. For control group, mean for
wound surface area was found as 32.40 + 5.58
mm2, and for aspartame group, the mean was 21.25
+ 2.59 mm2. According to the results of independent
samples t test analyses, the two groups were found to
be significantly different in wound healing (p < 0.05),
and aspartame had a better healing effect.
Figure 4. Effect of aspartame solution on CAM before (a) and after 24 h (c). In images (b) and (d), the same vessels with
(a) and (c) were highlighted with yellow to be seen clearly. CAM: chorioallantoic membrane.




Ineffective þ1 þ2 Total
Control n 5 0 0 5
% 100.0 0.0 0.0 100.0
6 mM n 4 0 0 4
% 100.0 0.0 0.0 100.0
15 mM n 3 2 1 6
% 50 33 17 100.0
30 mM n 2 2 1 5
% 40 40 20 100.0
60 mM n 0 3 2 5
% 0 60 40 100.0
Total n 14 7 4 25
% 56 28 16 100.0
CAM: chorioallantoic membrane.
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Histopathological examination showed that
aspartame-treated wounds had better healing (Fig-
ure 5). The thickness of granulation tissue and col-
lagen deposition were close to each other
comparing the control and aspartame groups. All the
specimens indicated a complete re-epithelization.
Therefore, aspartame-treated wounds showed enhanced
cellularity and increased angiogenesis compared with
the control group.
Discussion
Artificial sweeteners are added to a wide variety of
foods, drinks, drugs, and hygienic products.12 Since the
introduction of aspartame into the American food sup-
ply in 1981, it has grown to become the most widely
used and accepted artificial sweetener. Aspartame has
been the predominant artificial sweetener in the United
States for the past 25 years and is currently found in over
6000 food and beverage products.13 Although many sci-
entific papers have reported contradictory data about
aspartame’s safety, there are few studies explaining the
relation between aspartame and angiogenesis.3 The
strength of this study is the way it shows the effects of
aspartame on both in vivo and in vitro models.
In this study, we aimed to explain clearly the rela-
tion between aspartame and angiogenesis using both
in vivo and in vitro models because aspartame may
have a role in many diseases via angiogenesis.
According to the in vitro results of this study, it was
clearly seen that aspartame had a mild proliferative
effect on HUVECs in cell viability assay, during short
exposure times, similar to the results of Alleva et al.3
However, these results were not statistically significant.
CAM assay is a widely used in vivo method to ana-
lyze the effects of many different molecules on angio-
genesis at varied concentrations. In this study, we
examined the effects of aspartame at different concen-
trations (6–60 mM) on CAM assay. We found that
aspartame had an angiogenic effect especially at high
concentrations compared with the control group and
this was statistically significant. Also, we showed the
in vivo effects of aspartame on rat model of skin
wound healing and aspartame-treated wounds obvi-
ously showed better healing at a concentration of 50
mM, and the results were statistically significant. By
inducing angiogenic response, aspartame might have
a proangiogenic effect on CAM and wound healing
model in vivo. Thus, it is believed that aspartame had
similar effects on different species and increased
angiogenesis. US Food and Drug Administration has
set the acceptable daily intake (ADI) of aspartame
at 50 mg/kg of body weight. The European Food
Safety Authority has recommended a slightly lower
ADI of aspartame at 40 mg/kg. Aspartame concentra-
tions used in our in vivo models were much lower
than these recommended limits. In addition, our
results showed that increasing concentrations of
aspartame had stronger angiogenic effects. Past stud-
ies claimed that aspartame induces regenerative
cytokine production leading to the activation of
mitogen-activated protein kinases and resulting in
Figure 5. Aspartame-treated wounds (a) showed better angiogenesis and thus better healing compared with the control
group (b). Vessel formation seems to be much more in (a) than that of (b).
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the formation of new blood vessels.3 In our opinion,
a change on angiogenic switch with aspartame might
play an important role in neovascularization.
There are many contradictory studies about aspar-
tame and its negative effects on health.14,15 Many
diseases such as Alzheimer’s, phenylketonuria, conge-
nital defects, some types of cancer, lupus, and multiple
sclerosis are thought to have possible relation with
aspartame.16 The results of this study, which aims to
indicate the relation between aspartame and angiogen-
esis, showed that aspartame might have an inducing
effect on angiogenesis in vitro and in vivo models.
Long-term aspartame intake may have unfavorable
results on patients with diseases; those pathologic
bases are related to angiogenesis. Therefore, other
detailed studies, such as tumor models, are needed for
a final decision about worldwide usage of aspartame.
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